October 19, 2020

The Niche

Knoepfler lab stem cell blog

FDA crackdown on dubious stem cell clinics actually helps companies offering legitimate therapies

A while back, I did a post on the FDA audit report of Celltex and I think I made a mistake in the title of that post: Surprising FDA audit report of Celltex a blow to for-profit adult stem cell industry.

What I meant was the dubious stem cell industry. The title I used was too vague and implied too broad a conclusion.

I have since amended the title of that post to read:

Surprising FDA audit report of Celltex a blow to dubious, for-profit stem cell clinics

I hope that this clears up any confusion and I apologize.

I did not mean to include any of the legitimate adult stem cell companies as somehow negatively affected by the audit of Celltex. By legitimate I mean those that follow the FDA rules and get some solid science behind the treatments via pre-clinical studies and clinical trials BEFORE treating patients.

There a number of great adult stem cell companies, such as Osiris, out there working to help patients and in so doing also generate a profit, which is actually crucial to translating stem cell therapies to patients.

I would also note that I believe that the FDA cracking down on those clinics that do not follow the rules actually helps the legitimate clinics that are following the FDA rules. 

So cheers to the for-profit adult stem cell industry companies that play by the rules and help make research into a reality at the bedside in the form of stem cell-based regenerative medicine therapies.



%d bloggers like this: